Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

Imagem de Miniatura
Arquivos
art_HOFF_Cediranib_Plus_FOLFOX_CAPOX_Versus_Placebo_Plus_FOLFOX_2012.PDF (188.42 KB)
Citações na Scopus
116
Tipo de produção
article
Data de publicação
2012
Editora
AMER SOC CLINICAL ONCOLOGY
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
HOCHHAUS, Andreas
PESTALOZZI, Bernhard C.
TEBBUTT, Niall C.
LI, Jin
KIM, Tae Won
KOYNOV, Krassimir D.
KURTEVA, Galina
PINTER, Tamas
CHENG, Ying
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF CLINICAL ONCOLOGY, v.30, n.29, p.3596-3603, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signaling with activity against all three VEGF receptors. HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC). Patients and Methods Eligible patients were initially randomly assigned 1:1:1 to receive cediranib (20 or 30 mg per day) or placebo plus FOLFOX/CAPOX. In an early analysis of this and two other cediranib studies (HORIZON I [Cediranib Plus FOLFOX6 Versus Bevacizumab Plus FOLFOX6 in Patients With Previously Treated Metastatic Colorectal Cancer] and HORIZON III [Cediranib Plus FOLFOX6 Versus Bevacizumab Plus FOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer]), the 20-mg dose met the predefined criteria for continuation. Subsequent patients were randomly assigned 2: 1 to the cediranib 20 mg or placebo arms. Progression-free survival (PFS) and overall survival (OS) were coprimary end points. Results In all, 860 patients received cediranib 20 mg (n = 502) or placebo (n = 358). The addition of cediranib to FOLFOX/CAPOX resulted in PFS prolongation (hazard ratio [HR], 0.84; 95% CI, 0.73 to 0.98; P = .0121; median PFS, 8.6 months for cediranib v 8.3 months for placebo) but had no impact on OS (HR, 0.94; 95% CI, 0.79 to 1.12; P = .5707; median OS, 19.7 months for cediranib v 18.9 months for placebo). There were no significant differences in the secondary end points of objective response rate, duration of response, or liver resection rate. Median chemotherapy dose-intensity was decreased by approximately 10% in patients treated with cediranib. Adverse events (AEs) associated with cediranib were manageable. Conclusion Addition of cediranib 20 mg to FOLFOX/CAPOX resulted in a modest PFS prolongation, but no significant difference in OS. The cediranib AE profile was consistent with those from previous studies. Because of the lack of improvement in OS, cediranib plus an oxaliplatin-based regimen cannot be recommended as a treatment for patients with mCRC. J Clin Oncol 30:3596-3603. (C) 2012 by American Society of Clinical Oncology
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/1428
Referências
  1. AstraZeneca, 2011, GLOB POL BIOETH
  2. Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
  3. Cassidy J, 2008, J CLIN ONCOL, V26, P2006, DOI 10.1200/JCO.2007.14.9898
  4. Chen E, 2009, CLIN CANCER RES, V15, P1481, DOI 10.1158/1078-0432.CCR-08-0761
  5. Chiappa A, 2009, CRIT REV ONCOL HEMAT, V72, P65, DOI 10.1016/j.critrevonc.2008.11.003
  6. de Gramont A, 2000, J CLIN ONCOL, V18, P2938
  7. Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
  8. Drevs J, 2005, J CLIN ONCOL S, V23, p121s
  9. Ducreux M, 2011, INT J CANCER, V128, P682, DOI 10.1002/ijc.25369
  10. Ellis S, 2008, CONTEMP CLIN TRIALS, V29, P456, DOI 10.1016/j.cct.2007.10.008
  11. Goldberg Richard M, 2004, Clin Colorectal Cancer, V4 Suppl 1, pS9, DOI 10.3816/CCC.2004.s.002
  12. Goodwin R, 2010, ANN ONCOL, V21, P2220, DOI 10.1093/annonc/mdq221
  13. Hecht JR, 2011, J CLIN ONCOL, V29, P1997, DOI 10.1200/JCO.2010.29.4496
  14. Kohne CH, 2002, ANN ONCOL, V13, P308, DOI 10.1093/annonc/mdf034
  15. LoRusso P, 2011, INVEST NEW DRUG, V29, P1395, DOI 10.1007/s10637-010-9484-5
  16. Maindrault-Goebel F, 2007, J CLIN ONCOL S, V25, p166s
  17. Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
  18. Saltz LB, 2007, J CLIN ONCOL S, V25, p170s
  19. Schmoll H, 2010, ANN ONCOL S8, V21, pviii
  20. Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355
  21. Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
  22. Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
  23. Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
  24. WHITEHEAD J, 1989, STAT MED, V8, P1439, DOI 10.1002/sim.4780081204

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24